blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3250191

EP3250191 - TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  15.12.2023
Database last updated on 18.11.2024
FormerGrant of patent is intended
Status updated on  03.09.2023
FormerExamination is in progress
Status updated on  06.04.2019
FormerRequest for examination was made
Status updated on  03.11.2017
FormerThe international publication has been made
Status updated on  01.09.2017
Most recent event   Tooltip15.11.2024Lapse of the patent in a contracting state
New state(s): MC		published on 18.12.2024 [2024/51]
Applicant(s)For all designated states
Novo Nordisk A/S
Novo Allé
2880 Bagsværd / DK
[2017/49]
Inventor(s)01 / NISSEN, Birgitte
Novo Allé
2880 Bagsværd / DK
02 / NIELSEN, Flemming Seier
Novo Allé
2880 Bagsværd / DK
03 / GARIBAY, Patrick William
Novo Allé
2880 Bagsværd / DK
 [2017/49]
Application number, filing date16701684.928.01.2016
[2017/49]
WO2016EP51795
Priority number, dateEP2015015300029.01.2015         Original published format: EP 15153000
EP2015016258907.04.2015         Original published format: EP 15162589
WO2015EP5744207.04.2015         Original published format: PCT/EP2015/057442
EP2015018873707.10.2015         Original published format: EP 15188737
[2017/49]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016120378
Date:04.08.2016
Language:EN
[2016/31]
Type: A1 Application with search report 
No.:EP3250191
Date:06.12.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 04.08.2016 takes the place of the publication of the European patent application.
[2017/49]
Type: B1 Patent specification 
No.:EP3250191
Date:17.01.2024
Language:EN
[2024/03]
Search report(s)International search report - published on:EP04.08.2016
ClassificationIPC:A61K9/28, A61K9/50, A61K35/00, A61K38/26, A61P3/04, A61P3/10
[2023/38]
CPC:
A61K38/26 (EP,CN,US); A61K9/2886 (EP,CN,US); A61K35/00 (US);
A61K38/1709 (EP,US); A61K38/2278 (CN); A61K9/0053 (US);
A61K9/2013 (CN); A61K9/282 (US); A61K9/2846 (EP,CN,US);
A61K9/5026 (US); A61P3/04 (EP); A61P3/10 (EP);
A61P43/00 (EP) (-)
Former IPC [2017/49]A61K9/28, A61K9/50, A61K35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/49]  
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:TABLETTEN MIT GLP-1-AGONISTEN UND MAGENSAFTRESISTENTEM ÜBERZUG[2017/49]
English:TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING[2017/49]
French:COMPRIMÉS CONTENANT UN AGONISTE DE GLP-1 ET REVÊTEMENT GASTRO-RÉSISTANT[2017/49]
Entry into regional phase29.08.2017National basic fee paid 
29.08.2017Designation fee(s) paid 
29.08.2017Examination fee paid 
Examination procedure08.08.2017Date on which the examining division has become responsible
29.08.2017Examination requested  [2017/49]
19.03.2018Amendment by applicant (claims and/or description)
10.04.2019Despatch of a communication from the examining division (Time limit: M04)
09.07.2019Reply to a communication from the examining division
19.05.2020Despatch of a communication from the examining division (Time limit: M04)
25.09.2020Reply to a communication from the examining division
03.05.2021Despatch of a communication from the examining division (Time limit: M04)
08.09.2021Reply to a communication from the examining division
13.01.2023Despatch of a communication from the examining division (Time limit: M04)
19.01.2023Reply to a communication from the examining division
04.09.2023Communication of intention to grant the patent
11.12.2023Fee for grant paid
11.12.2023Fee for publishing/printing paid
11.12.2023Receipt of the translation of the claim(s)
Opposition(s)Opponent(s)01  17.10.2024  18.10.2024  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 [2024/48]
Former [2024/47]
Opponent(s)01  17.10.2024   
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
29.10.2024Invitation to proprietor to file observations on the notice of opposition
Fees paidRenewal fee
31.01.2018Renewal fee patent year 03
31.01.2019Renewal fee patent year 04
31.01.2020Renewal fee patent year 05
01.02.2021Renewal fee patent year 06
31.01.2022Renewal fee patent year 07
31.01.2023Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCZ17.01.2024
HR17.01.2024
MC17.01.2024
PL17.01.2024
RO17.01.2024
SK17.01.2024
SM17.01.2024
CH31.01.2024
NO17.04.2024
RS17.04.2024
GR18.04.2024
IS17.05.2024
[2024/51]
Former [2024/49]CZ17.01.2024
HR17.01.2024
PL17.01.2024
RO17.01.2024
SK17.01.2024
SM17.01.2024
CH31.01.2024
NO17.04.2024
RS17.04.2024
GR18.04.2024
IS17.05.2024
Former [2024/48]CZ17.01.2024
HR17.01.2024
PL17.01.2024
SM17.01.2024
CH31.01.2024
NO17.04.2024
RS17.04.2024
GR18.04.2024
IS17.05.2024
Former [2024/47]HR17.01.2024
PL17.01.2024
SM17.01.2024
NO17.04.2024
RS17.04.2024
GR18.04.2024
IS17.05.2024
Former [2024/36]HR17.01.2024
PL17.01.2024
NO17.04.2024
RS17.04.2024
GR18.04.2024
IS17.05.2024
Former [2024/34]HR17.01.2024
NO17.04.2024
RS17.04.2024
GR18.04.2024
IS17.05.2024
Former [2024/33]NO17.04.2024
IS17.05.2024
Former [2024/32]IS17.05.2024
Cited inInternational search[X]WO2009118722  (ORAMED PHARMACEUTICALS INC [IL], et al);
 [X]US2011142889  (LEE WILLIAM W [US], et al);
 [X]WO2014060472  (NOVO NORDISK AS [DK]);
 [X]WO2014191545  (NOVO NORDISK AS [DK]);
ExaminationWO2011084618
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.